Development of Vi conjugate - a new generation of typhoid vaccine.
about
The Burden of Typhoid and Paratyphoid in India: Systematic Review and Meta-analysisRevisiting typhoid fever surveillance in low and middle income countries: lessons from systematic literature review of population-based longitudinal studiesVaccines against invasive Salmonella disease: current status and future directionsThe effects of vaccination and immunity on bacterial infection dynamics in vivoWhat Have We Learned From the Typhoid Fever Surveillance in Africa Program?Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccineOverview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif®)Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young childrenUpdated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015.Diagnostics for invasive Salmonella infections: Current challenges and future directionsDifferential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 AntigenChallenges and Opportunities for Typhoid Fever Control: A Call for Coordinated Action.Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method.Changing Patterns in Enteric Fever Incidence and Increasing Antibiotic Resistance of Enteric Fever Isolates in the United States, 2008-2012.Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines.A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys.An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity.Preventing invasive salmonellosis in children through vaccination.[Vaccinations for international travelers].Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.Lessons Learned from Emergency Response Vaccination Efforts for Cholera, Typhoid, Yellow Fever, and Ebola.The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.NMR line-fitting quantification of polysaccharide N-acylurea-based modification in glycoconjugates of Salmonella Typhi Vi polysaccharide.Case fatality rate of enteric fever in endemic countries: A systematic review and meta-analysis.Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.Estimating Typhoid Fever Risk Associated with Lack of Access to Safe Water: A Systematic Literature ReviewWhy Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic Design
P2860
Q26747650-B5629DF3-02C6-49C9-8E56-AAFE5439C28AQ26773033-2DDB4AB5-DBA5-4421-BA4F-C65BBA3AA19EQ27007088-A95E1792-849B-4D52-8621-DD07CFD60546Q27324150-FCBA3A80-DD99-43B9-A862-2C64AD0DF426Q33362678-C5611F1E-3561-4AF6-B889-516D97510B40Q33666510-984F7FF1-842F-41D0-861A-BFCBB5FC8018Q33690625-DF49135E-66A5-4A3B-96D5-BF69995CF6FEQ33773373-B54A584F-062E-436B-A8A7-BAF62F509957Q33797264-E314D695-6722-4370-A7CE-1BB6DEF837FCQ34468771-487C07D5-42F2-4660-8352-3689DBAB2534Q35748638-7DDAC15C-741A-4C77-A95C-4BFD53FBFA36Q35888059-08F0C23F-4E6F-4340-83A0-7B2E14FB33B3Q36635681-2082237C-B766-400A-B399-4BDAB55F8863Q37094977-D05CD9B8-DE6B-4B22-AEEC-485A69E19C70Q37551292-C2DD7A99-160A-4B4E-8117-46C358B9B598Q38600784-585EBB38-2854-42BD-ACE5-5EB8760D01A0Q38672074-E203D49E-9B6E-4403-86DF-1984CDB3A233Q38685505-A3FA415C-425E-46E5-8CD2-3901720381A2Q38695279-2D02F300-B8DB-4396-8B30-4B4B03D17AB9Q39093233-8FE34D55-2957-4AFC-8F15-1D7AEDAB2574Q40107571-D3559E72-DA0F-4971-90A1-E506F7C184EEQ40218108-29FBAB17-A66A-4ECB-8902-1F3F50CC9A1EQ41008205-CE91C6BE-6FBC-440F-BDB2-21A983EC2886Q44106326-BBEACED1-2581-4433-984D-652E6DEFC77CQ47245287-10C282F9-6BD3-4E2E-9CAD-5AAD8FEBDCAEQ48351892-AB99F75C-14A2-457C-BAF9-20B586690E77Q52664616-436DC1BD-1205-4E85-B8F7-40C77A5B34D6Q55278055-6FE694D7-7B2F-4702-A4AD-173D1393D479Q56517610-AB8705D2-32D2-45EE-AB4A-5FFC28C84A84Q57946303-0289868A-2350-4057-A6CC-64A56DC60F32
P2860
Development of Vi conjugate - a new generation of typhoid vaccine.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Development of Vi conjugate - a new generation of typhoid vaccine.
@ast
Development of Vi conjugate - a new generation of typhoid vaccine.
@en
Development of Vi conjugate - a new generation of typhoid vaccine.
@nl
type
label
Development of Vi conjugate - a new generation of typhoid vaccine.
@ast
Development of Vi conjugate - a new generation of typhoid vaccine.
@en
Development of Vi conjugate - a new generation of typhoid vaccine.
@nl
prefLabel
Development of Vi conjugate - a new generation of typhoid vaccine.
@ast
Development of Vi conjugate - a new generation of typhoid vaccine.
@en
Development of Vi conjugate - a new generation of typhoid vaccine.
@nl
P2860
P1476
Development of Vi conjugate - a new generation of typhoid vaccine.
@en
P2093
Shousun Chen Szu
P2860
P304
P356
10.1586/14760584.2013.845529
P577
2013-11-01T00:00:00Z